CAPE TOWN, SA / ACCESSWIRE / July 21, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK: WUHN) (‘WGG’ or the ‘Company’), a biochemical company focused on alternative herbal cannabinoids and medical research to psilocybin, is pleased to announce the following update:
M2Bio Sciences Food & Beverage is pleased to announce the start of the M2Bio 10mg CBD soluble powder sachets. The pouches are the latest innovation from the company’s M2Bio brand product portfolio and offer adults the chance to enjoy CBD their own way. The bag contains high quality CBD isolate from Oregon, USA. Each sachet contains 10 mg of water-soluble CBD.
The convenient pre-packaged powder format makes it easy to mix the contents of the sachets into any drink quickly and easily. The versatility of the product allows the consumer to enjoy premium CBD in a variety of settings and for any occasion of their choice.
‘The M2Bio CBD sachets demonstrate the creativity, focus and expertise of M2Bio’s product development team and reaffirm our corporate commitment to growth through innovation. Consumers who have tried our Medspresso ™ CBD beverage range also inquired about CBD in its raw form. The water-soluble CBD powder gives customers the flexibility to infuse it with other foods and beverages as well. Ultimately, we want so many people to experience the health benefits of CBD and this is a step in the right direction. We created a process and product that combined science and individual taste to help adults discover new, personal CBD experiences, ”says Michael Sachar, CEO of M2Bio Sciences Food and Beverage.
The main features of the M2Bio CBD sachets include the following:
- Customizable: Can be easily added to almost any drink, turning it into a CBD-soaked drink in seconds.
- Fast: M2Bio sachets quickly dissolve into beverages for a quick, hassle-free CBD experience. Additionally, the nanoemulsion formula offers improved absorption compared to traditional edibles and other delivery mechanisms.
- Discreet: M2Bio sachets are odorless and blend into most beverages, making them a discreet addition. It also doesn’t contain any additional flavor.
- Co-branding opportunities: The nature of the product offers a perfect co-branding opportunity with any beverage maker, healthcare sector, retailer, hospitality, travel and tourism industries.
The bags will be available to consumers in four formats:
- Single Portion Pouches – 10 mg CBD, available at select retail stores at the POS.
- Pack of 5 sachets – 10 mg CBD x 5.
- Box of 60 sachets – 10 mg CBD x 60. Monthly delivery.
- Bulk orders for B2B – 10 mg CBD x> 2000 sachets.
About Wuhan General Group, Inc./ M2Bio Sciences, Inc
Wuhan General Group, Inc. (DBA M2bio Sciences), through its wholly owned subsidiary MJ MedTech, is a nutraceutical biotechnology company focused on medical research into alternative herbal cannabinoids and psilocybin, developing and marketing a range of CBD and mushroom products under its brands Dr. AnnaRx ™, Medspresso ™, Liviana ™ and Handcrafted Delights ™. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients with alcohol addiction, mental illness, and cardiovascular disease. Our mission is to bring botanical medicine to the forefront through the use of best practice science and medicine, clinical research and new technology. The company trades on the NASDAQ over-the-counter bulletin board under the symbol “WUHN”.
Listed company (OTC Pink: WUHN)
Follow us on Twitter: https://twitter.com/m2bio
Follow us on Facebook: http://www.facebook.com/m2bio
Follow us on Instagram: https://www.instagram.com/m2bio.sciences
Safe Harbor Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995 Any forward-looking statements contained therein include the intentions, beliefs or expectations of the company and members of its management team with respect to the future business of the company and the assumptions on which these statements are based. Potential investors are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and that actual results could differ materially from those anticipated in such forward-looking statements. Factors that could lead to these differences include, but are not limited to, failure to negotiate expected sales, lack of sales growth, customer engagement, failure to achieve improvements in performance, efficiency and profitability , and adverse developments relating to litigation or increased legal costs, the operation or performance of the Company’s businesses, or the market price of its common stock. Additional factors that could cause actual results to differ materially from those discussed in this press release can also be found on the company’s website. The company disclaims any responsibility to update forward-looking statements.
SOURCE: Wuhan General Group, Inc./M2Bio Sciences, Inc.
View source version on accesswire.com: